



Participation in Upcoming Investor Conferences

November 2, 2022

```
var w=window;if(w.performance||w.mozPerformance||w.msPerformance||w.webkitPerformance){var d=document;AKSB=w.AKSB||{};AKSB.q=AKSB.q||{};AKSB.mark=AKSB.mark||function(e,...)(new Date).getTime());AKSB.measure=AKSB.measure||function(e,...t)(AKSB.q.push(["measure",e,...t](new Date).getTime()));AKSB.done=AKSB.done||function(e)(AKSB.q.push(["done",e]));AKSB.mark("firstbyte",(new Date).getTime());AKSB.prof=(custid:"793678","ustr":"original:"0","clientrt:"1","ghostip:"23.220.107.144","ipv6:false,pct:"10","clientip:"34.224.172.69","requestid:"1a4c995a","region:"41485","protocol":"","bver:"14.akM:"dsca","akN:"ae","akTT:"O","akTX:"1","akTI:"1a4c995a","ai:"501146","ra:"false","pmgn":"","pmgi":"","pmp":"","qc":"","_sd:createElement("script"),_async:"async",_src:e,var t=d.getElementsByTagName("script"),t=(t.length-1).parentNode.insertBefore(_t))("https://ds-aksb-a.akamaihd.net/aksb.min.js")
RNS Number : 0728F
MaxCyte, Inc.
02 November 2022
```

MaxCyte to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, November 2, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Company management will participate in the following investor conferences:

- **Stifel Healthcare Conference**
Wednesday, November 16th at 3:00 p.m. Eastern Time
- **Stephens Annual Investment Conference**
Thursday, November 17th at 10:00 a.m. Eastern Time

Live and archived webcasts of the events will be available on the "Events" section of the MaxCyte investor relations website at <https://investors.maxcyte.com/>.

About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation™ technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell theravov sector, from discoverv and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
jd@maxcyte.com

US Media Relations
Seismic Collaborative, A Spectrum Science Company
Valerie Enes
+1 408-497-8568
valerie@teamseismic.com

Nominated Adviser and Joint Corporate Broker
Pannure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@lsegroup.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAEFAEEKAFKA